Completion of Novo Nordisk's Acquisition of Akero Therapeutics
Novo Nordisk has officially completed its acquisition of Akero Therapeutics Inc. This strategic business move marks a significant milestone for both companies, strengthening Novo Nordisk's position in the healthcare sector.
The Details of the Acquisition
Under this agreement, Novo Nordisk acquired all outstanding shares of Akero for a price of $54 per share in cash. This totals an impressive value of 4.7 billion USD, which exemplifies Novo Nordisk's commitment to advancing healthcare innovation. Additionally, shareholders will receive a non-transferable Contingent Value Right (CVR) that grants them the opportunity for further payments upon the regulatory approval of Akero's primary candidate, EFX.
Understanding EFX and Its Implications
Akero’s lead candidate, efruxifermin (EFX), is designed to treat compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The successful development and regulatory approval of EFX could usher in a new era of treatment options for patients suffering from this serious condition, showcasing the potential impact of this acquisition.
Akero Becomes a Wholly Owned Subsidiary
Following the completion of the deal, Akero Therapeutics will operate as a wholly owned subsidiary of Novo Nordisk. As a result, its common stock will no longer be listed or traded on the Nasdaq Global Select Market. This strategic move allows Novo Nordisk to fully integrate Akero’s innovations and talents into its broader mission of combating chronic diseases.
Novo Nordisk's Vision and Impact
Novo Nordisk is dedicated to driving change in healthcare, particularly in dealing with chronic diseases. Founded in 1923, the company has built a legacy deeply rooted in diabetes treatment and has expanded its expertise into various serious health issues. With a workforce of approximately 78,500 across 80 countries, Novo Nordisk is committed to pioneering scientific breakthroughs to enhance patient care globally.
Expanding Patient Access to Health Solutions
This acquisition not only signifies a financial investment but also represents an ongoing effort to provide better healthcare solutions to patients worldwide. Both companies share a vision of innovating patient care through research and development, aiming to provide solutions for unmet medical needs, particularly in metabolic diseases.
Navigating the Future of Healthcare Together
By bringing Akero’s groundbreaking research under its wing, Novo Nordisk is equipped to expedite the development of necessary treatments for patients facing physicians' challenges in metabolic diseases. This collaborative approach holds promise for future advancements in medical therapies, ultimately benefiting a larger patient population.
Contact Information for Further Inquiries
For media inquiries, you may reach:
Ambre James-Brown
Phone: +45 3079 9289
Email: globalmedia@novonordisk.com
Liz Skrbkova (US)
Phone: +1 609 917 0632
Email: lzsk@novonordisk.com
For investor relations, contact:
Jacob Martin Wiborg Rode
Phone: +45 3075 5956
Email: jrde@novonordisk.com
Sina Meyer
Phone: +45 3079 6656
Email: azey@novonordisk.com
Frequently Asked Questions
What marks the completion of the acquisition between Novo Nordisk and Akero?
The completion of the acquisition signifies that Novo Nordisk has fully acquired Akero and its assets, enhancing their market presence in metabolic disease treatments.
What was the purchase price for Akero's shares?
Novo Nordisk purchased Akero's shares for $54 USD per share, totaling approximately 4.7 billion USD.
What is the primary focus of Akero's lead candidate, EFX?
EFX focuses on treating compensated cirrhosis caused by MASH, addressing a significant unmet medical need in this area.
How does this acquisition benefit Novo Nordisk?
This acquisition enables Novo Nordisk to expand its portfolio and enhance research capabilities for innovative treatments targeting metabolic diseases.
Where can I find more information about Novo Nordisk and its activities?
For more insights, visit Novo Nordisk's official website or follow their social media channels for updates on their initiatives and health solutions.
